Oruka Therapeutics Inc
NASDAQ:ORKA

Watchlist Manager
Oruka Therapeutics Inc Logo
Oruka Therapeutics Inc
NASDAQ:ORKA
Watchlist
Price: 31.4 USD 1.98% Market Closed
Market Cap: 1.5B USD

During the last 3 months Oruka Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 94% over this period (open performance analysis).

The last transaction was made on Feb 14, 2025 by Venrock Healthcare Capital Partners Iii, L.p. , who bought 1m USD worth of ORKA shares.

Last Transactions:
Venrock Healthcare Capital Partners Iii, L.p.
$+1m
Venrock Healthcare Capital Partners Iii, L.p.
$+173.9k
Venrock Healthcare Capital Partners Iii, L.p.
$+106.4k
Venrock Healthcare Capital Partners Iii, L.p.
$+105k
Venrock Healthcare Capital Partners Iii, L.p.
$+6.3k
View All Transactions

During the last 3 months Oruka Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 94% over this period (open performance analysis).

The last transaction was made on Feb 14, 2025 by Venrock Healthcare Capital Partners Iii, L.p. , who bought 1m USD worth of ORKA shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
1
1.4m USD

Oruka Therapeutics Inc
Insider Trading Chart

Oruka Therapeutics Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Oruka Therapeutics Inc
Last Insider Transactions

Global
Insiders Monitor

Oruka Therapeutics Inc
Glance View

Market Cap
1.5B USD
Industry
Biotechnology

Oruka Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Westminster, Colorado and currently employs 4 full-time employees. The company went IPO on 2000-07-21. Oruka Therapeutics, Inc., formerly ARCA biopharma, Inc., is a biotechnology company. The firm is engaged in developing novel biologics designed for the treatment of chronic skin diseases, including plaque psoriasis. The company is advancing a proprietary portfolio of potential antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. The Company’s lead programs include ORKA-001 and ORKA-002, which are designed to block cytokines in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 is a potentially monoclonal antibody designed to inhibit IL-23p19 for the treatment of psoriasis. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19). ORKA-002 is a potentially monoclonal antibody designed to inhibit IL-17A/F for the treatment of psoriasis, psoriatic arthritis, and other conditions. ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F).

ORKA Intrinsic Value
10.35 USD
Overvaluation 67%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top